¿Cómo se compara el ratio PE de BAVA con empresas similares?

BAVA es un buen valor basado en su ratio Price-To-Earnings (13x) comparado con la media de empresas similares (45.5x).

¿Cómo se compara el ratio PE de BAVA con el de otras empresas de la industria European Biotechs ?

BAVA es un buen valor basado en su ratio Price-To-Earnings (13x) comparado con la media de la industria European Biotechs (26.8x).

¿Cuál es el ratio PE de BAVA comparado con su ratio PE justo? Este es el ratio PE esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

BAVA es un buen valor basado en su ratio Price-To-Earnings (13x) comparado con el ratio justo estimado Price-To-Earnings (21.6x).

¿Cuál es el precio justo de BAVA si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

BAVA (DKK185.3) cotiza por debajo de nuestra estimación de [[valor justo]] (DKK1206.37)

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

El precio objetivo es más de un 20% superior al precio actual de la acción, pero los analistas no están dentro de un rango de acuerdo estadísticamente seguro.

Bavarian Nordic (CPSE:BAVA) - Cotización, noticias y análisis

Resumen de acción BAVA

Bavarian Nordic A/S desarrolla, fabrica y comercializa vacunas que salvan vidas. Saber más

Análisis fundamental de BAVA
Puntuación del snowflake
Valoración	5/6
Crecimiento futuro	1/6
Rendimiento pasado	5/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Cotiza un 84.6% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 5.31%

Los beneficios aumentaron un 54.6% el pasado año

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Volatilidad del precio de la acción en los últimos 3 meses

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Competidores de Bavarian Nordic A/S

Genmab

CPSE:GMAB

DKK 92.1b

ChemoMetec

CPSE:CHEMM

DKK 7.8b

MannKind

NasdaqGM:MNKD

US$1.9b

PeptiDream

TSE:4587

JP¥333.7b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Bavarian Nordic
Precios históricos de las acciones
Precio actual de la acción	DKK 185.30
Máximo en las últimas 52 semanas	DKK 300.00
Mínimo de 52 semanas	DKK 143.40
Beta	1.58
1Cambio en 1 mes	-14.65%
Variación en 3 meses	-30.78%
Cambio de 1 año	21.23%
3Variación en 3 años	-38.34%
Variación en 5 años	11.63%
Variación desde la OPV	-27.33%

Noticias y actualizaciones recientes

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Nov 16

Recent updates

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Nov 16

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Aug 26

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Aug 25

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Aug 09

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Jul 11

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Rentabilidad de los accionistas

	BAVA	DK Biotechs	Mercado DK
7D	-11.2%	-11.8%	-3.1%
1Y	21.2%	-10.0%	5.7%

Rentabilidad vs. Industria: BAVA superó a la industria Danish Biotechs, que obtuvo un rendimiento del -10% el año pasado.

Rentabilidad vs. Mercado: BAVA superó al mercado Danish, que obtuvo un rendimiento del 5.7% el año pasado.

Volatilidad de los precios

Is BAVA's price volatile compared to industry and market?
BAVA volatility
BAVA Average Weekly Movement	7.7%
Biotechs Industry Average Movement	7.8%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

Precio estable de las acciones: El precio de las acciones de BAVA ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BAVA(8%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Danish.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	1,609	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S desarrolla, fabrica y comercializa vacunas que salvan vidas. La empresa ofrece vacunas no replicantes contra la viruela y la viruela del mono con los nombres IMVAMUNE, IMVANEX y JYNNEOS; vacuna antirrábica para uso humano con el nombre Rabipur/RabAvert; vacuna contra la encefalitis transmitida por garrapatas con el nombre Encepur; y vacuna contra el ébola con el nombre MVABEA. También está desarrollando MVA-BN para el tratamiento de la viruela; MVA-BN RSV, que se encuentra en ensayos clínicos de fase III para el tratamiento del virus respiratorio sincitial; ABNCoV2 que ha completado el ensayo clínico de fase III para el tratamiento del SARS-CoV-2.

Resumen de fundamentos de Bavarian Nordic A/S

¿Cómo se comparan los beneficios e ingresos de Bavarian Nordic con su capitalización de mercado?
Estadísticas fundamentales de BAVA
Capitalización bursátil	DKK 13.28b
Beneficios(TTM)	DKK 1.12b
Ingresos (TTM)	DKK 6.07b

13.0x

Ratio precio-beneficio (PE)

2.4x

Ratio precio-ventas (PS)

¿Está BAVA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BAVA
Ingresos	DKK 6.07b
Coste de los ingresos	DKK 2.33b
Beneficio bruto	DKK 3.74b
Otros gastos	DKK 2.62b
Beneficios	DKK 1.12b

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

Mar 05, 2025

Beneficios por acción (BPA)	14.24
Margen bruto	61.57%
Margen de beneficio neto	18.43%
Ratio deuda/patrimonio	0.1%

¿Cómo se ha desempeñado BAVA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BAVA

Recompensas

Análisis de riesgos

Competidores de Bavarian Nordic A/S

CPSE:GMAB

DKK 92.1b

CPSE:CHEMM

DKK 7.8b

NasdaqGM:MNKD

US$1.9b

TSE:4587

JP¥333.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Consensus EPS estimates increase by 56%

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Price target increased by 8.7% to kr.286

Second quarter 2024 earnings: Revenues exceed analyst expectations

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

New major risk - Share price stability

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 18%

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.